NLS Global report

The partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care.

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval of Eli Lilly's Foundayo (orforglipron), a once-daily GLP-1 tablet for weight management and type 2 diabetes in adults. If approved, it will compete with Novo's Wegovy pill in Europe.

Germany’s Merck KGaA has agreed to acquire London-based Silence Therapeutics, adding a Phase III-ready siRNA therapy for the rare blood cancer polycythemia vera (PV) to its rare disease pipeline.

Roche has signed a new strategic collaboration and license agreement with China’s Hansoh Pharma to develop novel antibody-drug conjugates (ADCs) across multiple cancer types. The deal could be worth more than USD 15 billion to Hansoh.

AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company's workforce in the state by more than 50%.

US President Donald Trump said on Friday September 18, 2026, that his administration plans to recommend that vaccine makers split certain childhood vaccines into five smaller doses given six months apart, which he expects to sharply reduce autism. He did not name the vaccines or cite evidence.